Long-term compassionate use of cefiderocol to treat chronic osteomyelitis caused by extensively drug-resistant Pseudomonas aeruginosa and extended-spectrum-β-lactamase-producing Klebsiella pneumoniae in a pediatric patient

Vista sencilla de ítem
dc.contributor.authorAlamarat, Zain I.
dc.contributor.authorBabic, Jessica T.
dc.contributor.authorTran, Truc T.
dc.contributor.authorWootton, Susan H.
dc.contributor.authorDinh, An Q.
dc.contributor.authorMiller, William R.
dc.contributor.authorHanson, Blake M.
dc.contributor.authorWanger, Audrey R.
dc.contributor.authorGary, Joshua L.
dc.contributor.authorArias, Cesar A
dc.contributor.authorPérez, Norma
dc.date.accessioned2020-05-11T23:39:29Z
dc.date.available2020-05-11T23:39:29Z
dc.date.issued2020
dc.description.abstractenglishWe report a 15 year-old Nigerian adolescent male with chronic osteomyelitis caused by an extensively drug-resistant (XDR) Pseudomonas aeruginosa strain of sequence type 773 (ST773) carrying blaNDM-1 and an extended spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae strain. The patient developed neurological side effects in the form of circumoral paresthesia with polymyxin B and asymptomatic elevation of transaminases with aztreonam (used in combination with ceftazidime-avibactam). Cefiderocol treatment for 14 weeks plus bone implantation resulted in apparent cure and avoided amputation. This Journal section presents a real, challenging case involving a multidrug-resistant organism. The case authors present the rationale for their therapeutic strategy and discuss the impact of mechanisms of resistance on clinical outcome. An expert clinician then provides a commentary on the case.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://aac.asm.org/lookup/doi/10.1128/AAC.00059-20
dc.identifier.issn0066-4804
dc.identifier.urihttps://hdl.handle.net/20.500.12495/2598
dc.language.isoeng
dc.publisherAmerican Society for Microbiologyspa
dc.publisher.journalAmerican society for microbiologyspa
dc.relation.ispartofseriesAmerican society for microbiology, 0066-4804, Vol. 64, Nro. 4, 2020spa
dc.relation.urihttps://aac.asm.org/content/64/4/e01872-19.long
dc.rights.creativecommons2019
dc.rights.localAcceso cerradospa
dc.subject.decsOsteomielitisspa
dc.subject.decsKlebsiellaspa
dc.subject.decsSalud del niñospa
dc.titleLong-term compassionate use of cefiderocol to treat chronic osteomyelitis caused by extensively drug-resistant Pseudomonas aeruginosa and extended-spectrum-β-lactamase-producing Klebsiella pneumoniae in a pediatric patientspa
dc.title.translatedLong-term compassionate use of cefiderocol to treat chronic osteomyelitis caused by extensively drug-resistant Pseudomonas aeruginosa and extended-spectrum-β-lactamase-producing Klebsiella pneumoniae in a pediatric patientspa
dc.typearticlespa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localartículospa

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Zain I. Alamarat, Jessica Babic, Truc T. Tran, Susan H. Wootton, An Q. Dinh, William R. Miller, Blake Hanson, Audrey Wanger, Joshua L. Gary, Cesar A. Arias, Norma Pérez_2020..docx
Tamaño:
11.85 KB
Formato:
Microsoft Word XML
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos